ALDER BIOPHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Non-cash gain on license of clazakizumab in exchange for investment in unconsolidated entity
Equity in net loss of unconsolidated entity
Depreciation and amortization
Loss on retirement of property and equipment
Stock-based compensation
Accretion of discount on convertible notes
Non-cash change in fair value of derivative liability
Other non-cash charges, net
Changes in operating assets and liabilities
Accounts receivable
Prepaid expenses and other assets
Inventory
Accounts payable
Accrued liabilities
Deferred rent
Deferred revenue

Purchases of investments
Proceeds from maturities of investments
Proceeds from sales of investments
Net cash used in operating activities
Investing activities
Purchases of investments
Proceeds from maturities of investments
Proceeds from sales of investments
Purchases of property and equipment
Proceeds from sale of property and equipment
Net cash provided by (used in) investing activities
Financing activities
Proceeds from issuance of 2025 convertible senior notes, net of offering costs
Proceeds from issuance of convertible preferred stock, net of offering costs
Proceeds from issuance of common stock, net of offering costs
Deferred offering costs
Proceeds from exercise of stock options and employee stock purchase plan
Effect of exchange rate changes on cash
Net increase (decrease) in cash and cash equivalents
Beginning of period
End of period
Net cash provided by financing activities

Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash
Beginning of period
End of period
Supplemental disclosures:
Purchases of property and equipment included in accounts payable and accrued liabilities
Conversion of convertible preferred stock into common stock
Cash paid for interest
Dividends on convertible preferred stock paid in kind

Comments